Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RGS12 | O14924 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2165402 | 0.85 | ALDH1A1 (0.50) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| SCHEMBL134713 | 0.85 | GAA (0.68) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| SCHEMBL1331519 | 0.82 | KDM4E (0.70) | KDM4ERGS12LMNAPOLBGAA | |
| SCHEMBL29503757 | 0.82 | KDM4E (0.70) | KDM4ERGS12LMNAPOLBGAA | |
| Hydrochloric Acid SCHEMBL28072109 | 0.81 | KDM4E (0.68) | KDM4ERGS12LMNAPOLBGAA | |
| SCHEMBL2165805 | 0.80 | ALDH1A1 (0.46) | HDAC1HDAC6KDM4EGAAMAPT | |
| SCHEMBL29939873 | 0.80 | HDAC1 (0.64) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| SCHEMBL28458350 | 0.80 | HDAC1 (0.64) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| SCHEMBL29939658 | 0.80 | HDAC1 (0.64) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| SCHEMBL8442558 | 0.80 | HDAC1 (0.64) | HDAC1HDAC6HDAC3HDAC2HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111548286-B | PSA derivative with HDAC3 inhibitory activity and application thereof | 沈阳药科大学 | 2022-09-06 | — | — | CN | disclosed |
| CN-111548286-A | PSA derivative with HDAC3 inhibitory activity and application thereof | 沈阳药科大学 | 2020-08-18 | — | — | CN | disclosed |
| EP-1992349-B1 | CGRP antagonists, their preparation and use as a medicament | BOEHRINGER INGELHEIM INT (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-8338473-B2 | Derivatives of psammaplin A, a method for their synthesis and their uses for the prevention or treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-12-25 | — | — | US | disclosed |
| US-8338473-B2 | Derivatives of psammaplin A, a method for their synthesis and their uses for the prevention or treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-12-25 | — | — | US | disclosed |
| EP-2137147-B1 | NOVEL DERIVATIVES OF PSAMMAPLIN A, A METHOD FOR THEIR SYNTHESIS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2011-07-13 | — | — | EP | disclosed |
| US-20100144716-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100120885-A1 | Novel Derivatives of Psammaplin A, A Method For Their Synthesis And Their Uses For The Prevention Or Treatment Of Cancer | RADBOUND UNIVERSITY NIJMEGEN (NL) | 2010-05-13 | — | — | US | disclosed |
| US-20100120885-A1 | Novel Derivatives of Psammaplin A, A Method For Their Synthesis And Their Uses For The Prevention Or Treatment Of Cancer | RADBOUND UNIVERSITY NIJMEGEN (NL) | 2010-05-13 | — | — | US | disclosed |
| US-7696209-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7528129-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-05 | — | — | US | disclosed |
| EP-1992349-A1 | CGRP antagonists, their preparation and use as a medicament | Boehringer Ingelheim International GmbH (DE) | 2008-11-19 | — | — | EP | disclosed |
| EP-1863791-B1 | 2-OXO-1,2,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-3-YL-PIPERIDINES USED AS CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008125988-A1 | NOVEL DERIVATIVES OF PSAMMAPLIN A, A METHOD FOR THEIR SYNTHESIS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-10-23 | — | — | WO | disclosed |
| EP-1964835-A1 | Derivatives of psammaplin A, a method for their synthesis and their use for the prevention or treatment of cancer | Centre National de la Recherche Scientifique (FR) | 2008-09-03 | — | — | EP | disclosed |
| CN-101146790-A | 2-okso-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidiner anvendt som cgrp-antagonister | BOEHRINGER INGELHEIM INT (DE) | 2008-03-19 | — | — | CN | disclosed |
| CN-101146799-A | Cgrp-antagonists, process for their preparation as well as their use as medicaments | BOEHRINGER INGELHEIM INT (DE) | 2008-03-19 | — | — | CN | disclosed |
| EP-1863791-A1 | 2-OXO-1,2,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-3-YL-PIPERIDINES USED AS CGRP ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| WO-2006100026-A1 | 2-OXO-1,2,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-3-YL-PIPERIDINES USED AS CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120885-A1 | Novel Derivatives of Psammaplin A, A Method For Their Synthesis And Their Uses For The Prevention Or Treatment Of Cancer | PSAP, PSAT1, SPAG5 | HDAC1 3182/4885HDAC6 1234/4885HDAC3 4157/4885 |
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | HDAC1 2048/4885HDAC6 3754/4885HDAC3 2038/4885 |
| US-20100144716-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | HDAC1 2048/4885HDAC6 3754/4885HDAC3 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.